Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific approvals

This article was originally published in The Gray Sheet

Executive Summary

FilterWire EX embolic protection device for saphenous vein graft treatment will launch the week of June 16. Cleared via 510(k), FilterWire is supported by the firm's FIRE equivalence study comparing the device with Medtronic/PercuSurge's GuardWire Plus. The trial demonstrated a 9.9% major adverse cardiac event rate for FilterWire versus 11.6% for GuardWire. FilterWire, obtained via the 2001 acquisition of Embolic Protection, Inc., also is being evaluated in the 40-center BEACH trial with Boston Scientific's Wallstent for a carotid stenting indication (1"The Gray Sheet" Feb. 18, 2003, p. 14). On June 10, the company also announced FDA and European CE mark approval of its Cutting Balloon Ultra, intended to access lesions unreachable by the previous-generation device...
Advertisement

Related Content

Boston Scientific Carotid Stent 2004 Launch Will Court Vascular Surgeons
Boston Scientific Carotid Stent 2004 Launch Will Court Vascular Surgeons
Advertisement
UsernamePublicRestriction

Register

MT018527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel